Which returned more over the last year, IGIB or XBI?

In the year to Sep 12, 2026, with distributions reinvested, IGIB returned −1.0% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.

Which is cheaper, IGIB or XBI?

IGIB charges 0.04% a year and XBI charges 0.35%, so IGIB is cheaper. Fees come from each fund's prospectus.

Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.

ETFIQetfiq.com · independent ETF data

IGIB vs XBI: how they differ

IGIB and XBI hold 0% of their weight in the same names, and XBI returned more over the year.

iShares 5-10 Year Investment Grade Corporate Bond ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.

What they hold in common

By the books each fund has filed, IGIB and XBI hold 0% of their money in the same securities at the same weight.

Largest positions each one holds and the other does not
Only in IGIB	Only in XBI
META PLATFORMS INC 0.24%	Apogee Therapeutics Inc 1.49%
AMAZON.COM INC 0.23%	Moderna Inc 1.41%
ANHEUSER-BUSCH CO/INBEV 0.20%	Twist Bioscience Corp 1.41%
BANK OF AMERICA CORP 0.20%	Oruka Therapeutics Inc 1.38%
BANK OF AMERICA CORP 0.20%	Kymera Therapeutics Inc 1.36%
BANK OF AMERICA CORP 0.20%	Viking Therapeutics Inc 1.31%
MARS INC 0.19%	Praxis Precision Medicines Inc 1.29%
PFIZER INVESTMENT ENTER 0.19%	Erasca Inc 1.27%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.

IGIB and XBI on the fields both publish, as of Sep 12, 2026. Source: ETFIQ.
	IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF	XBI State Street(R) SPDR(R) S&P(R) Biotech ETF
Where it sits	Core index fund	Core index fund
Issuer	iShares	State Street
What it is	5-10 Year Investment Grade Corporate Bond	SPDR S&P Biotech
Total return, 1 year	−1.0%	+64.0%
S&P 500 over the same days	+17.5%	+17.5%
Gap to the S&P 500	−18.5 pts	+46.5 pts
Expense ratio	0.04%	0.35%
Holdings	2988	150

IGIB in plain words

IGIB is a bond fund tracking the 5-10 Year Investment Grade Corporate Bond. Over the year to Sep 11, 2026 it returned −1.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.04% a year. It sat 3.3% below its high of Feb 27, 2026 on Sep 11, 2026.

XBI in plain words

XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.

Questions people ask

Which returned more over the last year, IGIB or XBI?: In the year to Sep 12, 2026, with distributions reinvested, IGIB returned −1.0% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
Which is cheaper, IGIB or XBI?: IGIB charges 0.04% a year and XBI charges 0.35%, so IGIB is cheaper. Fees come from each fund's prospectus.

Other comparisons

Where to next

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

IGIB against XBI, ETFIQ, data as of Sep 12, 2026. Every figure is arithmetic on a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, IGIB against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/IGIB-XBI Free to use with attribution; the underlying files are at Open data.

A comparison is not a recommendation. Standards and sources